Drug Insights

Is Cefiderocol approved by the FDA?

26 June 2024
3 min read

Yes, Cefiderocol, marketed under the brand name Fetroja, is FDA approved. The U.S. Food and Drug Administration (FDA) approved Cefiderocol on November 14, 2019, for the treatment of complicated urinary tract infections (cUTIs) and hospital-acquired bacterial pneumonia (HABP), including ventilator-associated bacterial pneumonia (VABP).

What is Cefiderocol?

Cefiderocol is a cephalosporin antibiotic used to treat serious bladder or kidney infections in adults, as well as pneumonia developed in hospital settings or during the use of a ventilator. This antibiotic works by inhibiting cell wall synthesis, which is vital for bacterial survival.

Indications and Usage

Cefiderocol is specifically indicated for:

  • Complicated Urinary Tract Infections (cUTIs): Including pyelonephritis caused by susceptible Gram-negative microorganisms such as Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.
  • Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP): Caused by susceptible strains of Acinetobacter baumannii complex, Escherichia coli, Enterobacter cloacae complex, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Serratia marcescens.

Dosage and Administration

Cefiderocol is administered intravenously and must be given slowly over a period of three hours. The typical dosage for adults is 2 grams every 8 hours for 7 to 14 days, depending on the severity and type of infection.

Side Effects

Common Side Effects

  • Nausea, vomiting, diarrhea, constipation
  • Mouth sores
  • Cough
  • Abnormal liver function tests
  • Headache
  • Rash
  • Pain, redness, itching, bruising, or swelling around the IV needle site

Serious Side Effects

  • Severe stomach pain, watery or bloody diarrhea
  • Tremors, rigid muscles, seizures
  • White patches or sores inside the mouth or on the lips
  • Low potassium levels, leading to symptoms like leg cramps, constipation, irregular heartbeats, increased thirst or urination, numbness or tingling, muscle weakness

Warnings and Precautions

Cefiderocol can cause serious or life-threatening allergic reactions. Patients with a history of severe allergic reactions to antibiotics, particularly beta-lactams (penicillins, cephalosporins), should inform their healthcare provider before starting this medication.

How is Cefiderocol Given?

Cefiderocol must be mixed with a diluent and further diluted with another liquid in an IV bag before administration. It is important to follow the exact preparation and administration instructions provided by healthcare professionals. Each IV bag is for single use only and should be disposed of after one use.

Storage

Store cefiderocol vials in the original carton in a refrigerator to protect them from light. Once mixed, the solution should be stored at room temperature and used within 1 hour or stored in a refrigerator and used within 24 hours after reaching room temperature.

Conclusion

Cefiderocol (Fetroja) has been FDA-approved since November 14, 2019, for treating serious infections such as complicated urinary tract infections and hospital-acquired bacterial pneumonia. Its efficacy in treating multi-drug resistant Gram-negative infections makes it a valuable option in the antibiotic arsenal. Patients should be aware of potential side effects and follow their healthcare provider's instructions carefully to ensure safe and effective use.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Is Reblozyl approved by the FDA?
Drug Insights
4 min read
Is Reblozyl approved by the FDA?
26 June 2024
The U.S. Food and Drug Administration (FDA) approved Reblozyl on November 8, 2019, for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
Read →
The Latest Review Provides Detailed Analysis of CAR-NK and CAR-T Cell Therapies
Hot Spotlight
8 min read
The Latest Review Provides Detailed Analysis of CAR-NK and CAR-T Cell Therapies
26 June 2024
The improved version of CAR-T therapy, CAR-NK therapy, has recently attracted considerable attention from the academic and pharmaceutical sectors due to its increased tumor-specific targeting and cytotoxicity, cost-effectiveness and easier availability of NK cells, shorter large-scale production cycles, and enhanced efficacy in treating solid tumors.
Read →
Chugai collaborates with Helsinn to promote the antiemetic drug AKYNZEO
Hot Spotlight
6 min read
Chugai collaborates with Helsinn to promote the antiemetic drug AKYNZEO
25 June 2024
On June 12, Helsinn Healthcare announced the renewal of its distribution and licensing agreement with Chugai Pharma Europe to promote AKYNZEO® (a combination drug containing netupitant and palonosetron) in the UK and Ireland.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - Jun 25
Pharma Frontiers
12 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - Jun 25
25 June 2024
Jun 25th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.